ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Oil Prices Rise on Venezuela Sanctions and Nigeria Airstrikes Despite Annual Losses 
Russian Stocks End Lower as Energy and Mining Shares Weigh on MOEX Index 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Japan Plans $189 Billion Bond Issuance as Record Budget Signals Expansionary Fiscal Policy 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Asian Stock Markets Trade Flat as Holiday Liquidity Thins and BOJ Minutes Watched 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Taiwan Stock Market Ends Higher as Semiconductor and Energy Shares Lead Gains 
UBS Warns of Short-Term Risks as Precious Metals Rally to Record Highs 
U.S. Stock Index Futures Steady After S&P 500 Hits Record on Strong Economic Data 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
China to Tighten Crude Steel Output Controls and Export Regulation Through 2030 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
South Korea’s Hanmi Pharm Co., Celltrion Inc., and Dongbang FTL were among 27 drugmakers chosen to produce low-cost versions of Merck & Co.’s COVID-19 pill molnupiravir for low- and-middle-income countries.
The Medicines Patent Pool (MPP), an UN-backed public health organization, announced that it signed sublicense agreements with 27 generic drug manufacturers to produce molnupiravir to be supplied to 105 countries.
Celltrion will manufacture the finished drug and Dongbang FTL will produce ingredients, while Hanmi will do both.
The MPP signed a licensing agreement with the US drugmaker last year to boost global access for molnupiravir.
The South Korean government would support its three pharmaceutical companies involved in the deal by easing regulations and establishing a consultative entity involving government ministries and companies.
According to MPP, which works to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries, the companies offered the sublicense have demonstrated their ability to meet its requirements for production capacity, regulatory compliance, and the ability to meet international standards for quality-assured medicines.
The MPP’s list of 27 generic manufacturers also includes 10 Indian and two Chinese firms.
Out of the 27 companies, 13 will produce both raw ingredients and the finished drug, according to the MPP.
